Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genomic Medicine Lab, |
RCV001375989 | SCV001572990 | likely pathogenic | Non-immune hydrops fetalis | 2020-06-04 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV001780276 | SCV002024608 | pathogenic | not provided | 2023-06-28 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV001780276 | SCV002049306 | likely pathogenic | not provided | 2021-07-30 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001780276 | SCV002246019 | pathogenic | not provided | 2024-03-08 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 598 of the PIEZO1 protein (p.Val598Met). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with autosomal dominant hereditary xerocytosis (PMID: 28619848, 30655378, 30887001, 31624108). ClinVar contains an entry for this variant (Variation ID: 1065463). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PIEZO1 protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects PIEZO1 function (PMID: 28619848, 30887001, 31091145). For these reasons, this variant has been classified as Pathogenic. |
Mayo Clinic Laboratories, |
RCV001780276 | SCV002573758 | likely pathogenic | not provided | 2021-12-06 | criteria provided, single submitter | clinical testing | BP4, PM2, PS3, PS4_moderate |